Standout Papers

Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Le... 2009 2026 2014 2020 494
  1. Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer (2009)
    José Baselga, Semiglazov Vf et al. Journal of Clinical Oncology

Immediate Impact

1 by Nobel laureates 3 from Science/Nature 64 standout
Sub-graph 1 of 21

Citing Papers

Deciphering breast cancer: from biology to the clinic
2023 Standout
Therapeutic resistance to anti-oestrogen therapy in breast cancer
2023 Standout
12 intermediate papers

Works of Jutta Steinseifer being referenced

Neoadjuvant giredestrant (GDC-9545) plus palbociclib (P) versus anastrozole (A) plus P in postmenopausal women with estrogen receptor–positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Final analysis of the randomized, open-label, international phase 2 coopERA BC study.
2022
LBA14 Neoadjuvant giredestrant (GDC-9545) + palbociclib (palbo) vs anastrozole (A) + palbo in post-menopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Interim analysis of the randomised, open-label, phase II coopERA BC study
2021
and 2 more

Author Peers

Author Last Decade Papers Cites
Jutta Steinseifer 967 476 518 15 1.4k
Linnea Chap 1033 359 651 28 1.7k
Brian J. Yoder 659 315 455 22 1.4k
D. Frye 1452 394 298 20 1.9k
Amy P. Sing 1332 420 494 32 1.9k
P Hurteloup 958 419 282 31 1.9k
Mohammad Jahanzeb 938 531 346 32 1.5k
Blair Marshall 624 504 786 10 1.7k
Mariantonietta Colozza 999 298 347 36 1.4k
Grazyna Liebérman 1057 393 526 9 1.7k
Thomas E. Seay 1708 492 253 20 2.2k

All Works

Loading papers...

Rankless by CCL
2026